HOME >> BIOLOGY >> NEWS
Giant pandas have plenty of genetic diversity

Even though there are only about 1,000 giant pandas left, there is hope for this beloved endangered species. A comprehensive genetic analysis of three wild giant panda populations shows that they still have enough genetic diversity to recover.

"From a strictly genetic perspective, the giant panda species and the three populations look promising...they have retained a large amount of diversity in each population," say Lu Zhi of Peking University in Beijing, China, Stephen O'Brien of the Laboratory of Genomic Diversity at the National Cancer Institute in Frederick, Maryland, and their co-authors in the December issue of Conservation Biology.

Despite its status as the "poster animal" of endangered species, little is known about the remaining populations of giant pandas in the wild. Historically, giant pandas lived in forests from China to northern Burma and Vietnam, but extensive deforestation has restricted the species to six alpine forest fragments in the rugged mountain ranges along the Tibetan plateau in western China. Assisted by conservation organizations, the Chinese government has recently stepped up efforts to protect the pandas: since 1993 the number of reserves has more than doubled (from 14 to 33), and they are monitored and patrolled more frequently.

However, biologists estimate that the remaining giant pandas are divided into about 25 populations with fewer than 20 individuals each. Because small, isolated populations are more likely to die out, this increases the risk that the species will become extinc. Lu, O'Brien and their colleagues analyzed the genetic variation in giant pandas primarily from populations in three mountain ranges: one that is separated from the others by a 75-mile-wide valley (Qinling) and two that are adjacent (Minshan and Qionglai).

The researchers found that the giant panda has moderate genetic diversity compared other carnivores. "The giant pa
'"/>

Contact: Stephen O'Brien
obrien@ncifcrf.gov
301-846-1296
Society for Conservation Biology
30-Nov-2001


Page: 1 2

Related biology news :

1. Giant bloom fades, science continues
2. Scientist probes fossil oddity: Giant redwoods near North Pole
3. Giant icebergs, unprecedented ice conditions threaten Antarctic penguin colonies
4. From dolphins to the Giant Panda - chemistry at SeaWorld and the San Diego Zoo
5. Giant jellies invade Gulf of Mexico threatening shrimp fishery
6. Giant plant-eating dinosaur found; two cast skeletons to be unveiled
7. First Dinosaur Embryo Skin Discovered -- Unhatched Embryos Are First Ever Found Of Giant-Plant Eating Dinosaurs
8. Best chance to protect giant pandas
9. Nature reserves arent protecting pandas, study shows
10. Researchers determine genetic cause of Timothy syndrome
11. Rare childhood genetic syndrome identified

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Giant pandas have plenty genetic diversity

(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: